Waning Immunity Against Respiratory Syncytial Virus During the Coronavirus Disease 2019 Pandemic
Frederic Reicherz, Rui Xu, Bahaa Abu-Raya, Abdelilah Majdoubi, Christina Michalski, Liam Golding, Aleksandra Stojic, Marina Vineta, Madison Granoski, Zenon Cieslak, Anil Chacko, Neil Desai, Inna Sekirov, David Marchant, Pascal M. Lavoie
Abstract
Health jurisdictions have seen a near-disappearance of respiratory syncytial virus (RSV) during the first year of the coronavirus disease 2019 (COVID-19) pandemic. Over this corresponding period, we report a reduction in RSV antibody levels and live virus neutralization in sera from women of childbearing age and infants between May to June 2020 and February to June 2021, in British Columbia (BC), Canada. This supports that antibody immunity against RSV is relatively short-lived and that maintaining optimal antibody levels in infants requires repeated maternal viral exposure. Waning immunity may explain the interseasonal resurgence of RSV cases observed in BC and other countries.